John Vandermosten

Answer

CEO Philip Serlin explained that while they look at all sources, smaller private and public companies are the most promising, as they often have interesting assets but lack capital or development expertise. He stated that BioLineRx is in a stronger negotiating position now compared to the past because the company's validated development track record, proven by the FDA approval of motixafortide, resonates well with potential partners, making their development capabilities a key advantage.

Ask Fintool Equity Research AI

Answer

CEO Philip Serlin explained that the Effexxa royalty is tiered, starting at 18% and increasing with sales, and is supplemented by up to $87 million in potential commercial-based milestones. He clarified the Gloria Bio agreement includes development and regulatory milestones in addition to commercial ones. Regarding the asset search, Mr. Serlin stated the company is opportunistic but is prioritizing programs with a relatively short and lean clinical development path to a value-creating event, rather than focusing on massive indications that would require large, costly trials.

Ask Fintool Equity Research AI

Answer

The company explained that Effexxa royalties are tiered, starting at 18% and increasing with sales, supplemented by potential commercial milestones. Milestones from partners (Aramid, Gloria) are a mix of commercial, regulatory, and geographic triggers. For the new asset search, the focus is on opportunistic programs with short, lean clinical pathways to a value-creating event.

Ask Fintool Equity Research AI

Answer

CFO Ping Rawson explained that while Dyadic does not provide specific cash burn guidance, operating expenses are expected to remain at or below last year's levels, with the final burn rate dependent on product sales in Q3 and Q4. President & COO Joe Hazelton added that DNase-one is the most commercially ready product, with revenue expected first, while transferrin is projected for late 2025 or early 2026 pending completion of the commercial manufacturing process.

Ask Fintool Equity Research AI

Answer

CEO Mark Emalfarb and COO Joe Hazelton explained that the Fermbox deal involves an immediate profit-sharing split. Regarding the Proliant collaboration, they stated that sampling for recombinant human serum albumin is expected in Q2 2025, with orders to be taken in Q3, and no advanced orders have been placed yet. For non-dairy products, Hazelton identified lactoferrin as having the highest potential margin, but noted that alpha-lactalbumin likely has the largest overall market potential in terms of volume and value.

Ask Fintool Equity Research AI

Answer

The company responded that beyond a certificate of analysis, manufacturing must occur in an ISO-certified facility, but no formal regulatory agency review is needed. They currently hold three certificates of analysis (DNASE-1, bovine transferrin, bovine alpha-lactalbumin), plus two for albumin under the Proliant deal. Manufacturing difficulty varies by product; Dyadic's advantage lies in higher yields and lower costs, providing margin flexibility. The preference for recombinant versus animal-derived products depends on the market; recombinant is competitive in research due to purity and consistency, while animal-derived often dominates the food space on cost, a challenge Dyadic aims to overcome.

Ask Fintool Equity Research AI

Answer

COO Joe Hazelton clarified that beyond a certificate of analysis, an ISO-certified facility is required for manufacturing research-grade proteins. He and CEO Mark Emalfarb confirmed Dyadic has certificates for DNASE-1, bovine transferrin, bovine alpha-lactalbumin, and both human and bovine albumin via its Proliant partnership. Hazelton and Emalfarb explained that while some products are small-batch, Dyadic's high-yield platform provides a cost and margin advantage. Hazelton noted that market preference for recombinant versus animal-derived products depends on the application, with research and pharma increasingly favoring recombinant for its consistency and cleaner profile.

Ask Fintool Equity Research AI

Answer

The alpha-lactalbumin market is approximately $700 million, with a smaller but growing recombinant segment. The deal with the dairy company includes milestones and royalty payments. The C1 platform has evolved significantly, becoming more stable and validated by a successful Phase I human trial, making it a faster, lower-cost platform for vaccine antigens. Regarding the Proliant deal, the C1-produced human albumin is a new product line for Proliant, which currently focuses on bovine proteins, so it's a market expansion for them. While the product is expected to be cost-effective, specific margins for Proliant were not discussed.

Ask Fintool Equity Research AI

Answer

Dr. Michael DiMaio, Chairman of the Board, explained that the UK and Australian markets are currently being used to gather usage data to leverage for the U.S. launch, rather than for significant sales. For the handheld device, he stated it is being designed with components identical to the cart-based system, which should allow for a more streamlined 510(k) regulatory pathway using the cart as a predicate device.

Ask Fintool Equity Research AI

Answer

The company is working hard on the Snapshot M but cannot confirm an accelerated timeline. Post-approval, the primary focus remains the BARDA partnership, but the commercial team is preparing for broader market entry. The second half of the year will be focused on advancing the DeepView system under the BARDA contract and continuing Snapshot M development.

Ask Fintool Equity Research AI

Answer

Executive Chairman Dr. Michael DiMaio deferred to the Data Science Chief, who explained the Dice score is a standard metric measuring segmentation overlap that provides a balanced view of precision and recall, as requested by the FDA. Dr. DiMaio then stated that the company does not plan to deploy more units in the U.K. or Australia, but will instead focus on a 'deeper dive' to gather clinical feedback from the existing sites.

Ask Fintool Equity Research AI

Answer

CFO and General Counsel Vincent Capone clarified that the higher Q3 revenue was primarily driven by increased activity and higher reimbursement rates under the main BARDA PBS contract, not the MTEC award. Dr. Michael DiMaio, Chairman of the Board, added that upcoming milestones for the MTEC device include getting design feedback from the Brooke Army Medical Center. Mr. Capone concluded by reiterating the full-year 2024 revenue guidance of approximately $28 million, calling it a 'reasonable and conservative' target.

Ask Fintool Equity Research AI

Answer

CEO Todd Davis stated that Merck's global capabilities are expected to significantly accelerate the worldwide commercial rollout of O2Ver. SVP of Investments, Paul Hadden, clarified that Medtronic is the commercial partner for the AVIM therapy program, while Terumo is the partner for the Virtu SAB balloon.

Ask Fintool Equity Research AI

Answer

CEO Todd Davis stated the ZELSUVMI launch is 'fairly independent' of the merger timing, as the team and manufacturing are already in place. Lauren Hay, VP of Strategic Planning, commented that Filspari's full EU approval reinforces momentum but doesn't dramatically alter its trajectory. CFO Octavio Espinoza projected a balanced cadence for Captisol sales and a gradual uptrend for the royalty line through the year, consistent with tiered royalty structures.

Ask Fintool Equity Research AI

Answer

SVP Paul Hadden stated that using VYJUVEK as a pricing and penetration analog for D-Fi is a fair assumption. CFO Tavo Espinoza explained the CASI termination is not expected to have a material impact in 2025, as their direct license with Acrotech remains. Paul Hadden also confirmed an uptick in the deal pipeline, reiterating that the team has never been busier.

Ask Fintool Equity Research AI

Answer

CEO Todd Davis stated that Ligand's strategy is product-focused on high unmet clinical need, which provides the best defense against payer pressure, rather than following therapeutic area trends. For Captisol, he described its dominant market position as stemming from its high efficacy, broad applicability, and ease of use, which has led to its use in 16 approved products, making it a prolific drug delivery platform.

Ask Fintool Equity Research AI

Answer

Chief Commercial Officer Jaime Xinos explained that the specific outreach channels are still being finalized and will be tailored to the preferences of targeted physicians. She mentioned that potential methods include social media, email, in-person representatives, and virtual reps, with the ultimate goal of meeting providers where they are most receptive.

Ask Fintool Equity Research AI

Answer

Jaime Xinos (executive) explained that initial payer feedback is directional and indicates formulary placement will depend on price, but cytisinicline's differentiation from generics is clear. She stated that instead of funding new pharmacoeconomic studies, Achieve will leverage existing literature and focus on demonstrating how cytisinicline's adherence profile improves outcomes. She confirmed the company is heavily leveraging agency partners like Omnicom and Credera for its digital launch strategy. Regarding launch timing, she noted that as a smaller company, Achieve will require some time post-approval to get the drug into the channel before sales commence.

Ask Fintool Equity Research AI

Answer

Chief Commercial Officer Jaime Xinos viewed the pregnancy topic as a long-term market expansion opportunity and noted the vaping data reinforces the need for a true cessation therapy. CEO Richard A. Stewart confirmed that resources are being prioritized to ensure product availability at launch. Chief Medical Officer Dr. Cindy Jacobs revealed that they have conditional FDA approval for a brand name but are not disclosing it publicly yet, though work on brand identity is underway.

Ask Fintool Equity Research AI

Answer

CEO Rick Stewart and CCO Jaime Xinos highlighted Dr. Rubinstein's value in honing messaging and medical strategy due to his direct experience as a practitioner in the nicotine dependence field. Regarding the trial cost, Rick Stewart indicated it would likely be similar to previous Phase III trials, with more specific guidance to be provided after the protocol is finalized with the FDA.

Ask Fintool Equity Research AI

Answer

CEO Brian Markison confirmed the new formulation is expected to "completely replace" the current one. He believes it will enable a "return to growth" by leveling the reimbursement playing field and winning back customers who have experienced poor performance with a competing F-18 agent. He also noted the new formulation will have a wider delivery radius.

Ask Fintool Equity Research AI

Answer

President Paul Blanchfield explained that launching a radio-equivalent like PNT2003 is justified by a positive financial return, a sizable market, and the strategic benefit of creating a theranostic pair with OCTEVY. CEO Brian Markison stated that any tau therapeutic would benefit from their sensitive imaging agents (MK-6240, PI-2620) for better patient selection, noting MK-6240 is already used in numerous sponsored and academic trials.

Ask Fintool Equity Research AI

Answer

CEO Brian Markison confirmed that Lantheus has 100% control of the acquired assets. He added that Radiopharm Theranostics as a whole looks interesting due to its development portfolio, and Lantheus's investment allows them to stay close and support the management team, leaving the door open for future partnerships.

Ask Fintool Equity Research AI

Answer

Chairman & CEO David Dodd stated that their manufacturing proposal was selected by BARDA but is in a 'holding basket' pending funding availability, and confirmed the Gideptin trial will use pembrolizumab. Mr. Dodd and Chief Medical Officer Dr. Kelly McKee explained that recent guidance aligns perfectly with their strategy of focusing their multi-antigen COVID vaccine on immunocompromised populations, reinforcing their current clinical focus.

Ask Fintool Equity Research AI

Answer

Executive Dror Bashan stated that partner Chiesi's commercial patient recruitment for Elfabrio is strong and improving quarterly, but specific sales numbers are confidential. He confirmed an application for less frequent dosing is under review by the EMA and U.S. plans will be updated when available. Regarding PRX-115, Bashan declined to compare it to specific competitors before Phase II data is available. Executive Eyal Rubin clarified that most of the 2020 warrants expired unexercised, with 908,000 exercised and approximately 12.5 million expiring.

Ask Fintool Equity Research AI

Answer

Executive Eyal Rubin confirmed Chiesi revenues are entirely from product sales but cautioned that a simple gross margin calculation would be misleading due to varying product margins. Executive Dror Bashan added that the BRIGHT study extension data is not new and Chiesi is discussing it with regulators. He stated the PRX-115 Phase II trial is planned for a 12-month duration, starting in H2 2025 with results expected in early 2027. Regarding Japan, the trial is ongoing, and it is considered a unique market.

Ask Fintool Equity Research AI

Answer

Executive Dror Bashan explained that as a private company, Chiesi's specific payer negotiations are not public, but confirmed they are performing well with market penetration in the U.S. and Europe. He stated it is too early for sales guidance due to the lumpy nature of inventory-building orders but reiterated that Protalix is pleased with Chiesi's efforts and maintains a very good, multi-disciplinary relationship with them. Executive Eyal Rubin added that the full PRX-115 data is expected around early November and that the company plans to attend the ACR conference.

Ask Fintool Equity Research AI

Answer

Executives Dror Bashan and Eyal Rubin responded. Bashan deferred sharing full PRX-115 PK data until all cohorts are complete but confirmed the anaphylactic reaction was an isolated, resolved incident. He also noted Phase II sites would likely expand to the U.S. and other continents, and that PRX-115 would be the primary R&D focus. Rubin clarified that the increase in contract liability was due to cash received from partner Chiesi for product that has not yet been recognized as revenue, indicating strong ongoing commercial activity. Regarding the Japan study, Rubin stated it is ongoing but could not provide a timeline for a BLA submission as it is Chiesi's proprietary data.

Ask Fintool Equity Research AI

Answer

Executive Talat Imran confirmed that partner ProGen has completed its Phase 1, is in a Phase 2a, and plans to file a U.S. IND for its subcutaneous drug. He explained that this parallel development is advantageous for Rani, as it allows them to leverage ProGen's data on dosing and titration to make RT-114's clinical studies faster and more efficient, with a potential for regulatory advantages down the line.

Ask Fintool Equity Research AI

Answer

If a deal is signed, focus will shift to obesity and the RT-105 program. Manufacturing automation is progressing well, with a pilot line planned for Phase III trials. The company views itself as creating novel 'bio-better' products, not competing directly on price as a biosimilar, thus differentiating its strategy from the broader biosimilar market trends.

Ask Fintool Equity Research AI

Answer

The company expects to share data confirming sustained drug delivery to colon tissue with low plasma concentration over multiple doses. BioJet partnership discussions have intensified as the company drives a process to select a partner for clinical development. The negotiation strategy focuses on maximizing value while retaining optionality. Future capital structure improvements are expected to follow upcoming clinical data catalysts, which could improve market capitalization.

Ask Fintool Equity Research AI

Answer

The executive confirmed that all controllable aspects for the BT-600 trial (supply, sites, CROs) are being prepared to start immediately after the expected FDA clearance in November. For BioJet, the current focus is on generating data within research collaborations to enable future partnership discussions. A new collaborator would benefit from existing data and progress faster than earlier ones.

Ask Fintool Equity Research AI

Answer

Chairman and CEO Harry Simeonidis stated that Australian sales are expected in Q1 2023, with the U.S. market being a two-year goal. He noted the cortisol test market is under analysis and results from the saliva-blood study are expected in late Q1 or early Q2 2023. Philip Hand, Executive Chairman of IFP, described the U.K. police project as a large, active market with significant interest. CFO Spiro Sakiris explained that grant funding is milestone-based and reimburses expenses already incurred, with the next reimbursement expected shortly.

Ask Fintool Equity Research AI

Answer

President and CEO Harry Simeonidis explained that ideal distribution partners must have an existing large footprint for rapid market access and strong relationships with healthcare and regulatory bodies. Regarding clinical protocols, he confirmed ongoing discussions and a pending presubmission with the FDA, expected by the end of the calendar year. For the manufacturing facility, a site is expected to be secured by the end of the current quarter, with the full build-out timeline dependent on sourcing high-tech equipment.

Ask Fintool Equity Research AI

Answer

President and CEO Sunil Bhonsle explained that the partnership with Indegene began in late June, with the first campaign launching in early August, and expects to see growth in the following quarters. Executive Director of Commercial Operations Joe Schrei added that they anticipate significant improvement by Q4. Bhonsle also noted that while Indegene is a global company, this is their first product in the addiction space. Regarding supply, he clarified that European shipping delays were due to specific EU regulatory modifications at a US facility and will not impact US or Canadian supply. Executive Chairman Marc Rubin tempered expectations, stating that while a 50% Q4 enrollment increase is a goal, it is not official guidance, though meaningful increases are expected.

Ask Fintool Equity Research AI

Answer

President and CEO Sunil Bhonsle explained that while an online prescription processing hub is operational, new patient starts have been limited by restricted facility access during the pandemic. He also noted minor communication delays in the supply chain but no major product shipment issues. On Europe, the launch with Molteni is still targeted for H2 2020, with manufacturing preparations in the final stages. EVP and Chief Scientific Officer Dr. Kate DeVarney added that a fully virtual REMS training program is awaiting FDA approval to address a backlog of interested providers, with a notable increase in interest from nurse practitioners and physician assistants. She also clarified that the revised nalmefene development plan will be funded by reallocating existing NIDA grant funds.

Ask Fintool Equity Research AI

Answer

CEO Geert Cauwenbergh and Chief Development Officer Gerrit Dispersyn clarified that RXI-762 is being developed with multiple partners, including CCIT and Iovance, for different applications to avoid overlap and maximize its potential. They confirmed it is the same molecule across partnerships, but tested within each collaborator's proprietary protocols. Gerrit Dispersyn explained that due to the nature of TIL therapy, animal models are not the likely next step, potentially accelerating the timeline to clinical trials. Principal Accounting Officer Caitlin Kontulis added that the BioAxone grant is active through Q3 2018, with second-year funding contingent on meeting specific NIH aims.

Ask Fintool Equity Research AI

Answer

President and CEO Dr. Geert Cauwenbergh stated that a competitor's RNAi approval would validate the entire field, signaling that RNAi therapies have 'arrived' and would benefit all companies in the space. Regarding the asset out-licensing, he confirmed RXi has engaged an experienced intermediary, a former investment banker, to professionally manage the high volume of interest.

Ask Fintool Equity Research AI

Answer

CFO Michael Jebson detailed the expected cash burn, projecting $5-5.5 million in G&A for the year and $2.5 million in remaining R&D costs for the LEVO-CTS study closeout, with sufficient capital through H1 2018. CEO John Kelley explained that Health Canada often benchmarks against European approvals and might view the drug differently than the FDA. Kelley also clarified that the trial protocol permitted standard-of-care interventions for blood pressure, such as vasopressors, and that dose titration was common in the Levosimendan arm to manage it.

Ask Fintool Equity Research AI

Answer

CEO John Kelley reported that the number of active LEVO-CTS trial sites has been consolidated from 79 to approximately 60. He confirmed that enrollment remains concentrated in top-performing sites like the Cleveland Clinic, which has enrolled over 50 patients. Regarding sales force incentives, Kelley stated that the company has not yet determined a structure.

Ask Fintool Equity Research AI